Maplight Therapeutics (NASDAQ:MPLT) CFO Vishwas Setia Sells 14,904 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CFO Vishwas Setia sold 14,904 shares of Maplight Therapeutics stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $28.11, for a total value of $418,951.44. Following the sale, the chief financial officer directly owned 377,723 shares in the company, valued at approximately $10,617,793.53. This trade represents a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Wednesday, May 6th, Vishwas Setia sold 10,564 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.24, for a total value of $298,327.36.
• On Tuesday, May 5th, Vishwas Setia sold 10,903 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total value of $307,464.60.

Maplight Therapeutics Trading Up 4.0%

MPLT stock opened at $29.04 on Thursday. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The firm has a market capitalization of $1.24 billion and a P/E ratio of -0.73. The business’s 50-day moving average price is $22.60.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Research analysts predict that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright assumed coverage on Maplight Therapeutics in a report on Monday. They set a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. TD Cowen assumed coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating on the stock. Needham & Company LLC initiated coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price objective on the stock. Finally, Canaccord Genuity Group initiated coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.43.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: HC Wainwright opened/updated coverage and issued detailed quarterly and FY estimates alongside a Buy rating and a $45 price target (implies ~55% upside from the recent price); the report provides a near‑term analyst catalyst and a bullish valuation anchor. HC Wainwright coverage (MarketBeat)
• Positive Sentiment: Needham reaffirmed its Buy rating on MPLT, reinforcing sell‑side support that can sustain buying interest. Needham reaffirmation (The Globe and Mail)
• Neutral Sentiment: Morningstar quote/coverage appears in the tape (useful for tracking consensus/third‑party data) but contains no new fundamental update by itself. Morningstar MPLT quote
• Negative Sentiment: Significant insider selling reported May 4–6: CEO Christopher Kroeger sold multiple blocks (~23,701 shares on May 6 and earlier sales), CFO Vishwas Setia, and insiders James W. Lillie and Erin P. Foff also sold material stakes. These transactions reduce insider holdings and may add near‑term supply pressure, though each sale was made under pre‑arranged Rule 10b5‑1 plans (which weakens the signal that sales reflect new negative company information). See CEO Form 4 filing. CEO Form 4 (SEC)
• Negative Sentiment: Additional insider Form 4 filings for James W. Lillie and Erin P. Foff confirm multi‑day sales at similar prices (May 4–6). Investors should monitor total sold vs. remaining insider ownership and trading volume to gauge impact. James W. Lillie Form 4 (SEC)

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Fcpm Iii Services B.V. acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $56,672,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $49,154,000. Goldman Sachs Group Inc. acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $17,060,000. Finally, 5AM Venture Management LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.